Goldman Sachs
CTXR icon

Goldman Sachs’s Citius Pharmaceuticals CTXR Stock Holding History

Goldman Sachs’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,518
Closed -$19K – 6066
2024
Q3 		$19K Sell
1,518
-45,944
-97% -$773K ﹤0.01% 5677
2024
Q2 		$693K Buy
47,462
+43,963
+1,256% +$788K ﹤0.01% 4649
2024
Q1 		$78.5K Sell
3,499
-203
-5% -$3.71K ﹤0.01% 5279
2023
Q4 		$70K Sell
3,702
-2,470
-40% -$46.8K ﹤0.01% 5343
2023
Q3 		$106K Sell
6,172
-3,526
-36% -$83.8K ﹤0.01% 5172
2023
Q2 		$291K Buy
+9,698
New +$319K ﹤0.01% 5023
2023
Q1 		– Sell
-534
Closed -$10.5K – 5963
2022
Q4 		$10.5K Buy
+534
New +$14.6K ﹤0.01% 5747
2022
Q3 		– Sell
-8,850
Closed -$203K – 6304
2022
Q2 		$203K Buy
8,850
+2,889
+48% +$79.2K ﹤0.01% 5629
2022
Q1 		$267K Buy
5,961
+3,626
+155% +$143K ﹤0.01% 5723
2021
Q4 		$90K Sell
2,335
-5,550
-70% -$252K ﹤0.01% 6160
2021
Q3 		$401K Buy
7,885
+3,334
+73% +$167K ﹤0.01% 5331
2021
Q2 		$396K Buy
+4,551
New +$274K ﹤0.01% 5354
2017
Q4 		– Sell
-463
Closed -$36K – 6385
2017
Q3 		$36K Buy
+463
New +$36.1K ﹤0.01% 6328

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Goldman Sachs's CTXR Position: Q4 2024 in Review

Goldman Sachs sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 1,518 shares — an estimated $19K sold.

Goldman Sachs first reported a position in CTXR in Q3 2017 and held it in 13 quarters. The position peaked at $693K in Q2 2024. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Goldman Sachs reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Goldman Sachs sold 1,518 Citius Pharmaceuticals shares in Q4 2024, an estimated $19K.
  • Goldman Sachs first reported a position in Citius Pharmaceuticals in Q3 2017 and held it in 13 quarters.
  • Goldman Sachs's Citius Pharmaceuticals position peaked at $693K in Q2 2024.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.